Thursday 16 October, 2025
Objectives: Chemotherapy-induced neutropenic episodes are associated with the risk of developing the life threatening condition febrile neutropenia (FN) (fever ≥…
Read morePoster: Applications- Oncology
Comparison of Inter-Occasion and Inter-Individual Variability in Chemotherapy- Induced Myelosuppression
Thursday 16 October, 2025
Objectives: A semi-physiological model of chemotherapy-induced myelosuppression has previously been developed and applied to several different anticancer drugs. Consistency in…
Read moreThe Shape of the Myelosuppression Time-course is Related to the Probability of Developing Neutropenic Fever in Patients with Docetaxel-induced Grade IV Neutropenia
Thursday 16 October, 2025
Objectives: Chemotherapy-induced neutropenic episodes are associated with the risk of developing the life-threatening condition febrile neutropenia (FN), defined as fever…
Read morePharmacokinetic-Pharmacodynamic Modeling of the Angiogenic Factors VEGF, sVEGFR-2, sVEGFR-3 and sKIT following Sunitinib Treatment in GIST
Thursday 16 October, 2025
Objectives: An identified relationship between suitable biomarkers and tumor response could potentially improve measures of treatment activity and facilitate treatment…
Read morePopulation PK-PD modeling of E7820 and α2-integrin expression on platelets in patients with solid tumors and lymphomas
Thursday 16 October, 2025
Introduction: The novel angiogenesis inhibitor E7820 was evaluated in a phase I dose escalation study in patients with malignant solid…
Read moreEvaluation of clinical dosing of E7820 from preclinical and clinical data using a biomarker
Thursday 16 October, 2025
IntroductionThe novel anti-cancer agent E7820 inhibits angiogenesis by inhibition of mRNA expression of α2-integrin.[1] It has shown to induce tumor…
Read morePopulation Pharmacokinetic Analysis of Trastuzumab (Herceptin®) based on Data from Three Different Dosing Regimens.
Thursday 16 October, 2025
Objectives: Herceptin® (trastuzumab) is currently indicated for the treatment of HER2 overexpressed metastatic breast cancer (MBC) and HER2 positive early…
Read morePopulation pharmacokinetics of a novel anticancer drug, RH1, in terminal cancer patients.
Thursday 16 October, 2025
Introduction & Objectives: RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone) is a new bioreductive drug that has been developed as a cytotoxic agent with selectivity…
Read morePopulation PK modeling and simulation to select a dosing schedule in Phase II trials for a novel TKI agent with time-dependent and nonlinear PK
Thursday 16 October, 2025
Objectives: Compared to other TKI agents, TKI258 additionally targets FGFR. Over 2 fold of induction of plasma VEGF was observed…
Read moreA fully integrated PK/IVTI/IVE model in mouse to help design the FHD trial for a cell cycle inhibitor X
Thursday 16 October, 2025
Objectives: The primary objective of this modelling study was to describe the effect of compound X on the cell cycle…
Read more